Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.
about
Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxisHuman Immunodeficiency Virus Diagnostic Testing: 30 Years of EvolutionPoint of Care Technologies for HIVThe characteristics of screening and confirmatory test results for HIV in Xi'an, China.Streamlining HIV testing for HIV preexposure prophylaxis.Performance of the Liaison XL Murex HIV Ab/Ag test on clinical samples representing current epidemic HIV variants.Prolonged second diagnostic window for human immunodeficiency virus type 1 in a fourth-generation immunoassay: are alternative testing strategies required?A signal-to-cutoff ratio in the Abbott architect HIV Ag/Ab Combo assay that predicts subsequent confirmation of HIV-1 infection in a low-prevalence setting.Decreasing Proportion of Recent Infections among Newly Diagnosed HIV-1 Cases in Switzerland, 2008 to 2013 Based on Line-Immunoassay-Based AlgorithmsPerformance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithmNucleic acid testing by public health referral laboratories for public health laboratories using the U.S. HIV diagnostic testing algorithm.Evaluation of Novel Multiplex Antibody Kit for Human Immunodeficiency Virus 1/2 and Hepatitis C Virus Using Sol-Gel Based MicroarrayCosts per Diagnosis of Acute HIV Infection in Community-based Screening Strategies: A Comparative Analysis of Four Screening AlgorithmsPerformance of Determine Combo and other point-of-care HIV tests among Seattle MSM.Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots--performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification.Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.Molecular HIV screening.Acute infections, cost and time to reporting of HIV test results in three U.S. State Public Health Laboratories.Residual risk of transmission of human immunodeficiency virus and hepatitis C virus infections by blood transfusion in northern Brazil.Economic evaluation of universal prenatal HIV screening compared with current 'at risk' policy in a very low prevalence country.Comparison of 4th-Generation HIV Antigen/Antibody Combination Assay With 3rd-Generation HIV Antibody Assays for the Occurrence of False-Positive and False-Negative Results.Clinical application evaluation of two fourth-generation human immunodeficiency virus (HIV) screening assays in West China Hospital.Performance evaluation of a new fourth-generation HIV Ag/Ab combination electrochemiluminescence immunoassay - evaluation of a new HIV assay.Rapid HIV screening: missed opportunities for HIV diagnosis and prevention.Screening for infectious diseases among newly arrived asylum seekers, Bavaria, Germany, 2015.No time to delay! Fiebig stages and referral in acute HIV infection: Seattle Primary Infection Program Experience.
P2860
Q22242951-96C199A1-4329-4CC5-8377-E04DB5CD071CQ28066053-8AAE90DE-EC8C-4426-AD81-AEDEB32078A2Q30442547-409DA821-650C-459C-BA72-28D35A3488A9Q33883784-4EA03F00-68FF-482F-99FE-B65BC122BF50Q34916430-87B19983-489D-4DB9-878A-9CC7A1D0832EQ35035727-D1CE1B2D-5DCB-4D38-AD75-0F6DC8264C00Q35036131-53FD4F3C-89F9-4A5A-BEFE-A5B0DA2D2E17Q35455665-060B9C76-F1FC-4C1D-9606-CAC0CEE0DF21Q35729544-F1A369B7-955E-4FE1-ACD3-8E8B10547280Q36092039-932B8D15-D2B6-4CA2-9F7D-86D392FDAB2DQ36100547-E2532FB6-5AE4-47CE-B1B6-D70451D281ECQ36109400-77C6BE12-D6BD-41A8-A7AE-6E4B414C2D62Q36497859-D04C06AB-D0C3-4051-B529-FF4FA8B5B2D7Q36604715-9E5FBE46-FD83-4C51-8D7F-FD1E00ED7FCBQ36689718-03019403-B758-4921-9488-0D629B272055Q36779718-341C958A-9477-4E36-9F72-75CBE815DE08Q38142249-645C3C3E-0147-4CA8-BEBA-1B1472893F17Q39727750-CC96518B-8DD2-4FC9-912D-3E3C4CC1B02FQ40169707-C4327766-186A-4BB6-95BD-3848C91F13ABQ40327623-40C18265-EDB3-4E83-8EFC-2DFA654EDBF8Q41280296-E8E4000A-7E78-40B1-B66F-577BF27F8E47Q42220435-D7B85077-103B-47B0-8CC1-2408605C6995Q42274760-7427CBE2-EA24-4772-9241-3E7FE9126E03Q46462542-C0BA530B-7AD5-4D51-9F84-60058AD78777Q52656590-10D87805-21FB-40CB-97C3-BD54AE0FD8B7Q53871083-2524E2FE-231A-4C8B-916C-69337D7C002E
P2860
Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.
@ast
Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.
@en
Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.
@nl
type
label
Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.
@ast
Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.
@en
Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.
@nl
prefLabel
Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.
@ast
Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.
@en
Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.
@nl
P2093
P1476
Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay.
@en
P2093
Kevin Delaney
Laura Wesolowski
Pollyanna Chavez
Pragna Patel
S Michele Owen
P356
10.1016/J.JCV.2011.09.010
P478
52 Suppl 1
P577
2011-10-07T00:00:00Z